Phaseline

Companies › Trethera

Trethera: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRE-515
Deoxycytidine kinase (dCK) inhibitor
DCKPhase 1Solid Tumor, AdultDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05055609TRE-515Phase 1Solid Tumor, AdultOncologyDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

DCK (1)

Companies with the same targets

CellSight Technologies Jiangsu Hansoh Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.